Forest Laboratories Inc.'s investment and option deal with Trevena Inc. last week will support the translation of a successful mechanism for treating chronic heart failure into the acute setting, as well as the development of additional programs based on biased interaction with GPCRs.

Trevena granted Forest an exclusive option to license exclusive worldwide rights to TRV027, a dual-acting ligand that inhibits angiotensin-mediated G protein signaling and stimulates arrestin beta signaling via the angiotensin II type I (ATI) receptor (AGTR1). The compound has completed a Phase IIa trial in acute heart failure.